Preview

Supply Chain Disruption Risk

Powerful Essays
Open Document
Open Document
10000 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Supply Chain Disruption Risk
Pre‐publication draft

Operational Strategies for Managing Supply Chain Disruption Risk1
Brian Tomlin Tuck School of Business at Dartmouth, Hanover, NH 03755 Yimin Wang W.P. Carey School of Business, Arizona State University, Tempe, AZ 85287 1. Introduction On June 16 2009, Genzyme Corporation announced that it had discovered the virus Vesivirus 2117 in one of the bioreactors at its plant in Allston, Massachusetts.2 While the virus strain is not thought to be harmful to humans, it does interfere with production efficiency. Genzyme made the decision to shut down production of the three drugs ‐ Cerezyme, Fabrazyme and Myozyme ‐ produced in the plant. In FY2008, Cerezyme and Fabrazyme (used for the treatment of Gaucher and Fabry diseases) accounted for $1.7 billion of the company’s $4.6 billion in revenue. Genzyme anticipated that the Allston plant would be back up and running by the end of July. However, because of the long processing lead time associated with biopharmaceuticals, production launched in August would not yield product until later in the year. At the time of the disruption, Genzyme was in the late stages of constructing a second facility in Framingham, Massachusetts for the production of Cerezyme and Fabrazyme. While the Framingham plant would provide an added layer of protection against any future interruptions in the production of Cerezyme and Fabrazyme, Genzyme’s only protection in June 2009 was its existing inventories of these two drugs. Unfortunately, the company’s stockpile was not large enough to fully absorb the production loss. Genzyme’s July 22 press release stated that: “Cerezyme and Fabrazyme inventories are not sufficient to avoid shortages during the period of suspended production and recovery. Genzyme is working closely with treating physicians, other health care providers,

You May Also Find These Documents Helpful

  • Good Essays

    Supply Chain Management

    • 1645 Words
    • 7 Pages

    In the San Diego distribution center (DC) information flow example, dealers not being notified automatically of order status would be classified as which of the following information flow dimensions:…

    • 1645 Words
    • 7 Pages
    Good Essays
  • Satisfactory Essays

    In order to remain competitive, a company must offer superior quality goods or services at the lowest prices possible. Supply chain enables a company to reduce the cost while increasing the efficiency. However, there are risks that are associated with such benefits. These issues should be properly addressed when a company is trying to rely heavily on supply chain management in order to stay competitive within its industry.…

    • 466 Words
    • 2 Pages
    Satisfactory Essays
  • Better Essays

    The Risk Management Plan is used as guidance to all the involved team members on managing the project wide risk levels and the team level risks. The process of risk management also allows the project to create strategies to efficiently and effectively attend to the potential obstacles that may arise to hinder the success of the project. When the project scope is clearly defined the foundations for developing the project plan are established. The project scope is basically a definition of the intended end results or the main mission of the…

    • 1150 Words
    • 6 Pages
    Better Essays
  • Satisfactory Essays

    When securing the modern enterprise, consider that IT systems do not operate alone. Securing them involves securing their interfaces with other systems as well. It is important to know the different interconnections each system may have.…

    • 312 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    Supply Chain Management

    • 29886 Words
    • 120 Pages

    Chapters 1/2: Introduction and Perspective ................................................................. 3 Chapter 3: Product Development Decisions................................................................. 7 Chapter 4: Procurement Decisions ............................................................................... 9 Chapter 5: Manufacturing Decisions........................................................................... 17 Chapter 6: Distribution Decisions ............................................................................... 25 Chapter 7: Transportation Decisions .......................................................................... 29 Chapter 8: Service Decisions ...................................................................................... 37 Chapter 9: Generate Demand Decisions..................................................................... 38 Chapter 10: Forecasting Decisions............................................................................. 44 Chapter 11: Information Technology Decisions ......................................................... 48 Chapter 12: Other Decisions ....................................................................................... 53 Chapter 13: Financial and Operating Reports............................................................. 55 Chapter 14: Research Studies..................................................................................... 73 Chapter 15: Performance Evaluation .......................................................................... 83 Chapter 16: Firm Management and Advice................................................................. 85 Appendix: Web-Based LINKS Access......................................................................... 87 Index…

    • 29886 Words
    • 120 Pages
    Powerful Essays
  • Best Essays

    Ldr 531 Week 5

    • 2421 Words
    • 10 Pages

    Plunkett, J. W. (August 19, 2010). Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2009. [Electronic version]. Biotechnology, Drugs & Genetics Industry. Retrieved October 24, 2010 from http://www.plunkettresearchonline.com…

    • 2421 Words
    • 10 Pages
    Best Essays
  • Satisfactory Essays

    Specific aspects of the Healthcare Reform Act also posed serious threat to Genentech 's business model. The passage of the Biologics Price Competition and Innovation Act allowed for a shortened approval pathway for biogeneric drugs, which would have a significant impact on Genentech, because of the significant costs associated with product development and testing in the industry.…

    • 1095 Words
    • 4 Pages
    Satisfactory Essays
  • Powerful Essays

    Tamiflu Case

    • 3403 Words
    • 14 Pages

    This expansion in manufacturing capacity has increased production of the drug to over 400 million treatments annually —…

    • 3403 Words
    • 14 Pages
    Powerful Essays
  • Good Essays

    Genzyme vs Biogen

    • 670 Words
    • 3 Pages

    Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. Its leading drugs are Cerezyme, Fabrazyme, Myozyme, Aldurazyme, Elaprase, Renagel and Renvela, and many others. It has about 7,000 employees. The current Chairman, President, & CEO is Henri A. Termeer. The company was founded in 1981 and is based in Cambridge, Massachusetts.…

    • 670 Words
    • 3 Pages
    Good Essays
  • Better Essays

    Genzyme Case Study

    • 894 Words
    • 4 Pages

    Henri Termeer started Genzyme Corporation with ten employees and then grew it to a corporation that now has four billion in sales per year. Genzyme is a biotechnology company that specializes in finding orphan drugs, which specifically cure enzyme deficiency conditions. To offer a brief explanation, an orphan drug is a pharmaceutical agent developed to cure a rare, orphan, disease. In order to find the cures for these rare diseases, technology using living biological systems and living organisms is used, which is known as biotechnology. In order for a biotechnology firm to succeed time is needed to give the firm the opportunity to find a successful product. According to Mr. Termeer, this requires that upon investing in a biotechnology firm you wait for results and the investment is long term.…

    • 894 Words
    • 4 Pages
    Better Essays
  • Good Essays

    Biogen Analysis

    • 7813 Words
    • 32 Pages

    Although Biogen has many advantages, it also has some definite weaknesses. Over 82% of its 2000 revenues came from Avonex, their cash cow. By relying on Avonex, Biogen has been able to stay profitable, but in the future this will not work. Biogen 's main threat comes from Serono, a Switzerland based company. Serono has a drug in their pipeline that has the potential of wiping out half of Biogen 's U.S. revenues. To continue into the future, Biogen must focus on the development of drugs in its pipeline. Biogen must stick with the larger blue-chip drug manufacturers in partnerships and also begin to look down the value chain and acquire smaller…

    • 7813 Words
    • 32 Pages
    Good Essays
  • Good Essays

    His company’s decision to raise the price of a lifesaving drug by more than 4,000 percent, from $1,130 to $63,000. An entrepreneur who acquired the rights to produce a life-saving drug then increased its price more than 50-fold overnight is defending his decision with assertions that the profits will help create better medicines in future. The Infectious Diseases Society of America and the HIV Medicine Association sent a joint, open letter to Turing Pharmaceuticals earlier in September, complaining that the sudden, steep price increase for Daraprim was “unjustifiable for the medically vulnerable patient population” and also that it was “unsustainable for the health care system. Shkreli said hiking the price of Daraprim was simply a “ business decision.” My initial reaction was that why would Shkreli want to raise the price that high even…

    • 449 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Launched in 1981 by Henry Blair, Genzyme Corporation is the fourth-largest biotech company in America. What differentiates Genzyme from its competition is that it uses living organisms or their products to generate drugs, rather than chemicals. Genzyme made its name in the industry with Ceradase, a treatment for Gaucher's disease. This drug was approved for sale in March of 1991 and had a market of 3000 people. Two years later a recombinant form of Ceradase was released and the company began to enter new markets…

    • 2078 Words
    • 7 Pages
    Powerful Essays
  • Satisfactory Essays

    medlmmune report

    • 780 Words
    • 4 Pages

    The underlying problem is that direct product cost of FluMist is too high to compete with the current available products. FluMist’s production period is considerably long. From 2002 to 2003 winter, only 4-6 million vaccines will be produced. The only way to lower cost is to product at a higher volume; nonetheless, the potential demand is only 15.9 million (Appx. 3), whereas the maximum production capacity is 50 million. Such high cost not only affect sales but also profitability. Net income falls by 28% with increased COGS, R&D, and SG&A. These costs went to FluMist production, acquisition of Aviron Inc., ongoing researches and advertising fee for…

    • 780 Words
    • 4 Pages
    Satisfactory Essays
  • Good Essays

    With the number increasing literally per day, the government and pharmaceutical businesses have decided to capitalize on their drug therapies. The U.S. National Cancer Institute was actually able to discover a drug referred to as “AZT” that could kill the human immunodeficiency virus (HIV). The company, Burroughs Wellcome (B-W), obtained the exclusive license to market the drug and was then allowed to set the price. Unfortunately, pharmaceutical companies typically attempt to recover their research and developmental costs by charging an arm and a leg for their product.…

    • 654 Words
    • 3 Pages
    Good Essays